1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Essex Bio-Technology Limited

Essex Bio-Technology Limited

HHKEX:1061
2.04
HKD
+0.01
(+0.25%)
1.51BMarket Cap
Mar 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.62
0.93
1.17
1.38
1.6
2.06
2.21
1.69
2.84
2.3
3.05
2.94
3.2
- -
Basic EPS, GAAP
0.1
0.14
0.19
0.24
0.3
0.4
0.52
0.38
0.6
0.39
0.48
0.54
0.56
- -
Free Cash Flow per Basic Share
0.04
0.03
0.08
0.1
0.23
0.18
0.12
-0.03
0.27
0.17
0.37
0.44
0.23
- -
Dividend per Share
0.01
0.02
0.02
0.02
0.06
0.06
0.07
0.05
0.09
0.09
0.07
0.1
0.13
- -
Book Value per Share
0.46
0.59
0.74
0.99
1.31
1.61
2.07
2.47
3.01
3.03
3.39
3.74
4.26
4.5
Tangible Book Value per Share
0.41
0.53
0.66
0.84
1.05
1.19
1.35
1.39
1.55
1.19
1.41
1.64
1.9
2.09
Basic Weighted Avg Shares
557
557
560
560
562
571
579
578
577
574
570
567
567
567
Sales/Revenue/Turnover
347
518
654
776
900
1,176
1,279
978
1,638
1,318
1,737
1,670
1,814
- -
Operating Margin (%)
21.57
19.17
20.23
21.33
20.98
22.11
25.71
22.51
25.21
21.36
19.25
21.26
22.79
- -
Depreciation Expense
3
10
10
13
18
20
28
28
33
42
60
56
63
- -
Net Income, GAAP
55
75
105
136
167
231
303
219
346
225
275
307
318
- -
Effective Tax Rate (%)
24.86
21.39
19.71
16
15.1
15.37
14
12.73
12.29
13.42
20.45
18.18
23.29
- -
Profit Margin (%)
15.82
14.52
16.04
17.57
18.6
19.64
23.64
22.38
21.13
17.11
15.85
18.4
17.54
- -
Working Capital
47
124
151
312
438
547
758
727
858
653
435
574
853
905
LT Debt
- -
- -
- -
121
129
189
350
360
409
382
56
114
278
249
Total Equity
254
331
413
557
739
929
1,197
1,426
1,734
1,731
1,924
2,124
2,413
2,549
Return on Invested Capital (%)
19.26
22.57
25.04
24.19
21.29
21.35
20.71
10.38
16.61
9.09
11.48
12.75
11.85
- -
Return on Capital (%)
19.63
22.81
25.2
24.46
21.72
23.55
22.98
12.38
16.51
10.41
12.8
13.79
12.78
- -
Return on Common Equity (%)
24.38
25.73
28.2
28.11
25.81
27.7
28.46
16.69
21.89
13.01
15.06
15.18
14.02
- -

Capital Structure

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
123
69
100
LT Borrowings
150
261
230
LT Finance Leases
17
17
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
567
567
566
Market Capitalization
2,500
2,138
1,511

Working Capital

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
1,442
1,620
1,689
Cash, Cash Equivalents & STI
643
784
808
Accounts Receivable, Net
614
657
669
Inventories
65
79
87
Total Current Liabilities
758
767
784
Payables & Accruals
- -
- -
- -
ST Debt
123
69
100
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.78%
11.31%
13.63%
Free Cash Flow
-91.92%
-178.25%
-47.1%
Net Income, GAAP
15.45%
12.09%
3.54%
Sales/Revenue/Turnover
13.5%
16.89%
8.62%
Total Cash Common Dividend
27.09%
26.17%
23.71%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,670
2025
- -
- -
1,814
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.54
2025
- -
- -
0.56
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.1
2025
- -
- -
0.13
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hian Leng Ngiam
Full Time Employees
1,289
Sector
Health technology
Industry
Medical specialties
Address
No. 88, Keji 6th Road, Hi-Tech Zone Hong Kong GD Hong Kong 519085
IPO Date
Jun 27, 2001
Website
essexbio.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Essex Bio-Technology Limited (1061.HK) develops, manufactures, and commercializes biopharmaceutical products focused on wound care, ophthalmology, and cardiovascular health. The company offers a portfolio of proprietary products including recombinant human acidic fibroblast growth factor gel (AFGF) for chronic wound healing under the Fiblast brand; nerve growth factor eye drops (NGF) for dry eye and neurotrophic keratitis under the Befiter brand; and recombinant human serum albumin for medical applications; alongside distribution of third-party products such as anti-bacterial artificial dermis, hyaluronic acid dermal fillers, and cardiovascular devices. Essex operates primarily in China with expanding presence in Hong Kong, Macau, and select international markets including Southeast Asia and Europe, targeting hospitals, clinics, and pharmaceutical distributors.[web:previous] Founded in 2004 and headquartered in Causeway Bay, Hong Kong, the company maintains research and development facilities and manufacturing sites in Zhuhai, China, through its subsidiaries Essex Zhuhai Bio-Technology Co., Ltd. and Essex Bio-Investment Ltd. Essex serves healthcare professionals and patients in dermatology, ophthalmology, and regenerative medicine segments, emphasizing innovative biologic therapies derived from recombinant protein technology.[web:previous] In recent developments, Essex Bio-Technology reported robust revenue growth in 2024, driven by strong demand for its core wound care and ophthalmology products amid China's aging population and healthcare reforms. The company expanded its product pipeline with regulatory approvals for new indications of NGF eye drops and advanced clinical trials for cardiovascular biologics as of mid-2025. Additionally, Essex strengthened its market position through strategic distribution partnerships in Southeast Asia and ongoing investments in manufacturing capacity upgrades in Zhuhai to support export growth.[web:previous]